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Background: Antimicrobial stewardship (AMS) is an important strategy of quality
improvement for every hospital. Leadership is an important factor for implementation
of quality improvement and AMS programs. Recent publications show successful AMS
programs in children’s hospitals, but successful implementation is often difficult to
achieve and literature of AMS in neonatal and pediatric intensive care units (NICU/PICU) is
scarce. Lack of resources and prescriber opposition are reported barriers. A leadership
style focusing on empowering frontline staff to take responsibility is one approach to
implement changes in health care institutions.
Aim: Literature review regarding empowering leadership and AMS in health care and
assessment of the impact of such a leadership style on AMS in a NICU/PICU over 3
years.
Methods: Assessment of the impact of a leadership change September 1, 2015
from control-driven to an empowering leadership style on antibiotic use and hospital
acquired infections. Prospective analysis and annual comparison of antibiotic use, rate
of suspected and confirmed ventilator-associated pneumonia (VAP) and central-line
associated blood stream infection (CLABSI) including antibiotic use overall, antibiotic
therapy for culture-negative and culture-proven infections including correct initial choice
and streamlining of antibiotics in the NICU/PICU of the Children’s Hospital of Lucerne
between January 1, 2015 and December 31, 2017.
Results: Five articles were included in the literature review. All five studies concluded that
an empowering leadership style may lead to a higher engagement of physicians. Three
out of five studies reported improved AMS as reduced rate in hospital-acquired infections
and improved prevention of MRSA infections. From 2015 to 2017, antibiotic days overall
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and antibiotic days for culture-negative situations (suspected infections and prophylaxis)
per 1000 patient days declined significantly from 474.1 to 403.9 and from 418.2 to 309.4
days, respectively. Similar, the use of meropenem and vancomycin declined significantly.
Over the 3 years, suspected and proven VAP- and CLABSI-episodes decreased with no
confirmed episodes in 2017.
Conclusion: An empowering leadership style which focuses on enabling frontline
physicians to take direct responsibilities for their patients may be a successful
strategy of antimicrobial stewardship allowing to overcome reported barriers of AMS
implementation.
Keywords: leadership, empowerment, shared leadership, distributed leadership, antimicrobial stewardship,
intensive care unit, pediatrics
INTRODUCTION
Quality improvement in healthcare has become one of the most
discussed topics of the Twenty-first century and has real potential
to enhance patients’ outcome. The emergence of outcome
measurement and quality improvement in the neonatal intensive
care units (NICU) showed a profound effect on improving
outcomes for premature neonates within the last decade (1).
Antimicrobial stewardship (AMS) is an important strategy of
quality improvement. The Infectious Disease Society of America
describe the primary goal of AMS as optimizing clinical outcomes
while minimizing unintended consequences of antimicrobial use,
including toxicity, the selection of pathogenic organisms, and
the emergence of resistance (2, 3). A recent published systematic
review regarding AMS in children’s hospitals showed significant
reduction of overall and/or selected antibiotic use in general
pediatric wards, whereas only limited information is available on
effective components of successful AMS programs in pediatric
and neonatal intensive care units (PICU/NICU) (4).
Antibiotics are among the most used medications in PICUs
and NICUs, often prescribed for culture-negative situations
(5–8). Especially neonates and young infants often present
with unspecific clinical and laboratory signs of infections and
empirical antibiotic therapy has to be started (9, 10). This is
mandatory, as delayed antimicrobial therapy causes increased
morbidity and mortality of truly infected children (9, 11). On the
other hand, inappropriate prescription of antibiotics may have
serious short-term consequences for children who eventually
do not suffer from infection: drug-related adverse events,
longer hospital stay, increased risk of fungal infections, rate of
necrotizing enterocolitis (NEC), healthcare costs and mortality
(12). In addition, alongside the known long-term consequences
of inappropriate antibiotic use such as antimicrobial resistance
Abbreviations: AMS, Antimicrobial stewardship; NICU, Neonatal intensive care
unit; PICU, Pediatric intensive care unit; VAP, Ventilator associated pneumonia;
CLABSI, Central line associated blood stream infection; MDSi, National minimal
data set intensive care; EOS, Early onset sepsis; LOS, Late onset sepsis; CRIB II,
Clinical risk index for babies II; PIM II, Pediatric index of mortality II; SAPS
II, Simplified acute physiology Score II; CDC, Center for Diseases Control and
Prevention; NEC, Necrotizing enterocolitis; ETT, Endotracheal tube; I:T ratio,
Immature neutrophils to total neutrophils; CRP, C-reactive protein; HAI, Hospital-
acquired infection.
(13–16), there is a growing body of evidence on the impact on
the human microbiome with potential consequences for future
health, especially when antibiotics are prescribed in the first
few years of life (10, 12, 14, 17, 18). Therefore, appropriate
pediatric AMS programs, particularly in NICUs and PICUs are
urgently needed (4, 9, 19). Successful implementation of AMS
is often a challenge due to the need of a high amount of staff
resources (20), specific staff education, the implementation of an
inter-professional AMS team, and lack of financial support from
hospital administrations (4, 16, 19, 21, 22). Prescriber opposition
due to the control-driven aspect of many AMS components may
be an additional barrier for efficient implementation (21). The
need for a strong leadership in these programs is oftenmentioned
but rarely defined. A leadership style focusing on empowering
frontline physicians to take over individual responsibility in the
application of AMS is a potential strategy to improve the outcome
of children receiving antibiotics or interventions, even when the
respective staff and financial resources for a comprehensive AMS
program are not available.
The aim of this study was first to perform a literature review
regarding empowering leadership style for physicians with a
specific focus onAMS. Secondly, we wanted to analyze the impact
of a leadership style empowering frontline physicians to take
decisions situational on AMS in our PICU and NICU over the
last 3 years. We hypothesized that, with this leadership style,
antibiotic days overall and antibiotic days for culture-negative
situations (suspected infections and prophylaxis) decreases.
In addition, we hypothesized that suspected hospital-acquired
infections and antibiotic days for suspected hospital-acquired
infections decrease.
METHODS
Literature Review
We conducted a literature review searching the database
PubMed according to following key words: “leader∗ AND
antimicrobial stewardship,” “shared leadership AND physician
AND patient outcome,” “distributed leadership AND health
care,” “empowerment AND antimicrobial stewardship,”
“empowerment AND front line AND patient outcome,”
such as “patient outcome AND leadership style NOT nurse.” As
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we focused on analyzing leadership styles among physicians and
especially with physicians as leaders and stakeholders/followers,
we excluded literature regarding leadership styles in nursing
or business and management journals without relation to
physicians. Comments, guidelines and reviews were excluded,
only quantitative and qualitative studies with focus on leadership
and AMS were included. The literature search was conducted
in June 2018 and sorted by best match. We then added articles,
which were either retrieved from reference lists or were
recommended by experts during various discussions.
Study Setting/Design
The Swiss national ethics committee (Project-ID 2018-00361)
approved this single center cohort study. All data used for this
study were anonymized and the Swiss national ethics committee
gave an assistant consent to use the necessary data. Inclusion
criteria: All neonates and pediatric patients hospitalized at the
NICU/PICU at the Children’s Hospital Lucerne between January
1, 2015 and December 31, 2017. On admission, the Clinical Risk
Index for Babies II [CRIB II, (23)] was used for preterm infants
<32 weeks of gestational age. The pediatric index of mortality
II [PIM II (24)] was used for preterm infants >32 weeks of
gestational age and children up to 15 years of age.
The Children’s Hospital Lucerne is a teaching hospital for
Pediatrics, Pediatric Surgery, and Neonatology. The NICU is a
referral level III unit (perinatal center) for central Switzerland
covering around 7000-8000 annual deliveries. The PICU cares
for children until 16 years of age with health issues from
all specialties except cardiac surgery. The NICU/PICU has an
accreditation for 11 intensive care beds with about 550–600
admissions per year. The unit is part of the national quality circle
for neonatology and pediatric intensive care and provides the
requested data of all admissions according to Swiss regulations.
Patient’s care in the NICU/PICU is provided by one team,
consisting of board-certified consultants for neonatology and/or
pediatric intensive care, fellows in training for neonatology
and/or pediatric intensive care and registrars following a 6-
month rotation while in training for general pediatrics. The
unit is led by a head consultant who reports to the head
of the department of pediatrics. Role descriptions: The head
consultant has the clinical and organizational lead of the unit and
the ultimate responsibility regarding patient management and
outcomes. He is the supervisor of all consultants. Consultants are
clinical supervisors of fellows and registrars: They have the daily
clinical lead of patient management and are actively involved
in regular rounds and prescription of medications. Fellows and
registrars conduct the regular rounds, are responsible for patient
admission, management, and prescriptions.
Leadership Style
End of August 2015, the clinical and organizational lead of the
unit changed. The former head left the hospital and the previous
deputy head took over. The rest of the physician team of the unit
remained mainly unchanged. Thereby leadership style changed
from control-driven to empowering leadership. Obviously, no
leader works just with one style, but the contrast of control-
driven versus empowering describes best the difference of the
two styles. Whereas there is no intent to compare the impact
of the diverse leadership styles, there is a possibility to describe
the impact of an empowering leadership style due to the distinct
change end of 2015.
The focus of leadership after the change was to support
and empower frontline physicians on the unit. Within a rough
guideline, physicians were asked to treat patients according to
their best knowledge within an inter-professional team at the
current moment. For example, at the end of 2015 the team
came to the agreement to employ an early extubation policy
with the goal of extubating patients as soon as possible, rather
than waiting to reach specific thresholds or senior approval to do
so. No additional request was asked. If doubtful, the physician
on-duty always had the possibility to ask senior colleagues for
advice. Adverse outcomes such as reintubation within 24 h after
extubation were used as a possibility to learn. Another example
for a difference within antimicrobial stewardship was related
to antibiotic treatment: The rough guideline requested to start
antibiotic therapy early in patients with suspected infections.
Prescription of the specific antibiotic drug and dose was advised
according to a concise, web-based internal guideline. On the
other hand, physicians were empowered to stop antibiotic
treatment as soon as a bacterial infection was considered to
be unlikely, in order to shorten therapy duration as much as
possible.
Antimicrobial Stewardship
The NICU/PICU surveillance program was initiated in
September 2014 with the goal of collecting prospective data
on antibiotic use (general antibiotic days and specifically days
with use of meropenem and vancomycin), ventilator associated
pneumonia (VAP), and central-line associated blood stream
infection (CLABSI). Daily records of patients, ventilation days,
suspected VAP, suspected CLABSI and number of patients on
antibiotic therapy were obtained by the physician on-duty. The
NICU/PICU data manager verified the collected information
and fed them regularly into the electronic database.
Since 2007, physicians at the Children’s Hospital Lucerne
prescribed medications (i.e., antibiotics) according to a web-
based internal guideline, which provides advice for correct
use and calculates weight-adapted medication dosage. These
guidelines were evaluated and adapted every year and since
2016 correspond to the guidelines for infection control of the
University Berne (Switzerland) (25). Since 2012, the decision
to stop antibiotic therapy in late preterm and term babies
with suspected early-onset sepsis was procalcitonin-guided, as
the unit was part of the Neonatal Procalcitonin Intervention
Study NeoPInS (26). Since the replacement of the units’
leadership, multifaceted changes followed: In December 2015,
weekly antimicrobial stewardship rounds were introduced with
the adult infectious disease specialist. From June 2016 a pediatric
infectious diseases specialist consulted the AMS rounds. The
“early extubation policy” as described above was initiated in order
to shorten duration of invasive ventilation. In January 2016, a
VAP-working group was established and their elaborated care
bundle was implemented in December 2016. The recommended
rules were described by Goerens et al. (27) as the following:
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“Hand hygiene before and after patient contact and handling
respiratory equipment, wearing gloves when in contact with
secretions, ventilator circuit changes every 14 days or when
visibly soiled, oral care every 2-4 hours, head of bed elevation,
draining ventilator condensate before repositioning of the
patient, using endotracheal tube (ETT) with cuff, choosing size
of the ETT carefully to reduce numbers of reintubation.”
Definitions
VAP
The unit’s surveillance program defined suspected VAP according
to the following criteria: duration of ventilation of at least 48 h
and requested new start or change of antibiotic due to worsening
of ventilation conditions and/or clinical deterioration and/or
radiological changes compatible with pneumonia and/or changes
of tracheal secretions and/or abnormal laboratory parameters
(CRP > 20 mg/l, leukocytosis/-penia, I:T ratio >0.2). Proven
VAP was defined according to the Center of Disease (CDC)
definition (28). In many NICUs, VAP incidence and concomitant
antibiotic use were not routinely assessed (29). Nevertheless,
suspected pneumonia and VAP is one of the main reasons for an
empiric antibiotic therapy in NICUs and therefore we included
the neonatal population for the assessment and evaluation of
VAP (8). This is in line with recent literature asking to increase
neonatologists’ interest for VAP (29). Ventilation days were
defined as days with invasive ventilation.
CLABSI
Suspected CLABSI was defined according to the following
criteria: central catheter in place for at least 48 h and new start
or change of antibiotic therapy necessary due to worsening of
clinical state and/or abnormal laboratory parameters (CRP > 20
mg/l, leukocytosis/-penia, I:T ratio >0.2). Proven CLABSI was
defined according to the CDC definitions (30). Catheter days
were defined as days with central-line in place.
Sepsis/Meningitis
Culture proven sepsis and/or meningitis were defined as
patients with blood and/or cerebrospinal fluid positive cultures.
We excluded patients if blood and/or cerebrospinal fluid
culture isolates were considered to be contaminants and the
clinical and/or laboratory course was inadequate for sepsis or
meningitis. Culture proven infections within the first 48 h of
hospitalization were analyzed as community acquired, after 48 h
of hospitalization as hospital acquired infections.
Correct Initial Use and Streamlining of Antimicrobials
In order to assess the use of antibiotics at the unit we evaluated
retrospectively empiric choice and streamlining. Streamlining
was defined as the first time of narrowing the antibiotic
spectrum after receiving results (i.e., Gram stain, identification of
germ with resistance pattern) from the microbiology laboratory.
Empiric choice of antimicrobial agent was defined according
to the web-based internal guideline of the hospital, which is
described above. For analysis, correct initial use was defined as
an antibiotic treatment that is either the perfect choice or an
acceptable choice of medication depending on the case. Likewise,
correct streamlining included cases with perfect streamlining,
cases in which streamlining was done but more than 24 h after
getting the results from the microbiology register and cases,
where streamlining was not required. The pediatric infectious
disease specialists of the Children’s Hospital in Lucerne (MB) and
of the Children’s Hospital in Zurich (CB) evaluated streamlining
and correct initial antibiotic use according to a 4-point Likert
scale (perfect, acceptable, not done, not applicable).
Outcomes
To ensure the comparability of the 3 years (2015, 2016, and 2017)
we aimed to compare the following baseline characteristics: CRIB
II, PIM II, number of admissions, number of patients, number of
preterm infants, ventilation days, catheter days and rate of proven
infections (early-onset: within 48 h of hospitalization; late-onset:
after 48 h of hospitalization).
The primary outcome was the annual comparison of
overall antibiotic days per 1000 patient days and antibiotic
days for culture-negative situations (suspected infections and
prophylaxis) per 1000 patient days.
The secondary outcomes were defined as: (i) specific antibiotic
days of meropenem and vancomycin per 1000 patient days; (ii)
the annual comparison of hospital-acquired infections (suspected
and confirmed VAP and CLABSI); (iii) antibiotic days for
hospital-acquired infections; (iv) antibiotic days for community
acquired and hospital acquired culture-proven infections (sepsis
and/or meningitis); and (v) the annual comparison of correct
initial antibiotic use and correct streamlining for culture-proven
infections. We focused on meropenem and vancomycin because
both antibiotics are determined as reserve medications within the
hospital. Nevertheless, prior to leadership change in September
2015, meropenem was used for treatment of severe abdominal
infections, vancomycin for suspected CLABSI.
Data Sources
For analysis of patients’ baseline characteristics, data were
retrieved from the Minimal Data Set inquiries (MDSi), which is
the mandatory data set by the Swiss Society for Intensive Care
Medicine (31). The MDSi collects information about number
of admissions, number of patients, patient characteristics as
age and weight, hospitalization days, PIM II and CRIB II
scores, ventilation days and catheter days, and mortality rates.
Data collected with the NICU/PICU surveillance program gives
information about the number of suspected VAP and CLABSI,
such as general antibiotic days, as well as meropenem and
vancomycin days. The microbiology register of the Hospital
of Lucerne provided the number of positive blood and/or
cerebrospinal fluid cultures with discrimination of early (<48 h
after hospitalization) versus late (>48 h after hospitalization)
onset sepsis. Details about antibiotic treatment, i.e., kind of
antibiotic, length of therapy, date, and time of start of treatment
and streamlining, were extracted from patient files and reports of
hospitalization.
Statistical Analysis
The rate of observed patient days by the NICU/PICU surveillance
program was compared with the number of true patient
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days retrieved from the MDSi. All results were calculated
for 1000 patient days, ventilation days, or catheter days,
respectively. Antibiotic days retrieved from the NICU/PICU
surveillance program (i.e., antibiotic days overall, meropenem,
and vancomycin days) were analyzed on the base of observed
patient days by the surveillance program. Antibiotic days
retrieved from the microbiology register and from patient files
(i.e., antibiotic days for culture-proven infections) were analyzed
on the base of true patient days according to the MDSi.
The parameters obtained during antimicrobial stewardship,
especially the outcomes mentioned in section 2.6, were analyzed
descriptively. In order to assess trends for antibiotic use,
e.g., in terms of antibiotic days per 1000 patient days or
similarly structured metrics, Cuzick’s nonparametric test for
trend (32) has been used. Fisher’s exact test has been applied
to investigate potential associations in contingency tables with
binary outcomes. Trends and effects for the incidence of certain
events have been evaluated utilizing Poisson regression (adjusted
for number of patient days, ventilation days or catheter days
where appropriate). Due to the exploratory nature of this
retrospective analysis, a significance level of alpha= 5% has been
applied without adjustment for multiplicity. However, trends and
effects characterized by distinct patterns in the point estimates,
supported by p-values of p < 0.01 or even p < 0.001, are
considered more likely to be robust.
RESULTS
Literature Review
Five articles were included in the review. Figure 1 illustrates the
selection process. An overview of the publications is shown in
Table 1. Most articles have been published within the last decade,
the oldest publication used in the review was published in 2006.
Three out of the five articles were qualitative studies. Three
studies encompassing leadership and AMS reported patient
outcomes. All five studies are in line with the conclusion that
an empowering leadership style in one way or another does
lead to a higher engagement of staff and/or stakeholders. To
share or distribute responsibilities on every team member, it is
important to build personal relationships within a team (34) and
to establish a penalty free learning culture (37). Positive impacts
were reported on culture changes and on AMS topics such as
MRSA prevention (35), reduction of nosocomial infections (37)
and CLABSI (36).
Study Population
During the study period (January 2015 to December 2017), a total
of 1567 patients were admitted to the NICU/PICU and included
in the study population. Baseline characteristics are listed in
Table 2. 6722 out of 7875 (85%) patient days were observed
within the PICU/NICU surveillance program. We observed a
downward trend of the annual number of ventilation days and
catheter days from 2015 to 2017 (p < 0.001). Mortality over the
study period showed a not significant, decreasing trend from
2.1% in 2015 to 1.5% in 2017 (Table 3).
Primary Outcomes
Annual antibiotic days per 1000 patient days declined
significantly from 474.1 in 2015, to 398.3 and 403.9 days
in 2016 and 2017, respectively (p < 0.001). Antibiotic days
for culture negative situations (suspected infections and
prophylaxis) decreased significantly from 418.2 in 2015, to
358.0 and 309.4 days per 1000 patient days in 2016 and 2017,
respectively (p < 0.001) (Table 3).
Secondary Outcomes
The use of meropenem and vancomycin decreased significantly
(p < 0.001) over the 3 years: Meropenem days per 1000 patient
days decreased from 53.2 in 2015, to 27.4 and 25.5 in 2016 and
2017, respectively; Vancomycin days from 86.8 in 2015, to 43.1 in
2016 and 33.1 in 2017.
During the 3 years we noted a decreasing tendency of
suspected and proven hospital-acquired infections: The rate
of suspected VAP-episodes decreased significantly from 26.2
per 1000 ventilation days in 2015 to 19.0 in 2016 and 9.2 in
2017 (p = 0.027). In 2015, 3.1 proven VAP-episodes per 1000
ventilation days were noted, whereas none in 2016 and 2017. The
rate of suspected CLABSI-episodes decreased not significantly
from 10.7 per 1000 catheter days in 2015 to 8.7 in 2016 and 6.7 in
2017 (p= 0.261). In 2015, 1.8 proven CLABSI-episodes per 1000
catheter days were noted, 0.6 in 2016 and none in 2017.
Antibiotic days per 1000 ventilation days for suspected VAP
declined from 214.4 in 2015, to 150.2 in 2016 and 56.9 in 2017
(p < 0.001). For proven VAP, in 2015 32.4 antibiotic days per
1000 ventilation days were noted, whereas none in 2016 and 2017
(p < 0.001). Antibiotic days per 1000 catheter days for suspected
CLABSI declined from 70.0 in 2015 to 63.7 in 2016 and 33.4 in
2017 (p < 0.001). For proven CLABSI, 17.8 antibiotic days per
1000 catheter days were noted in 2015, 4.3 in 2016 and none in
2017 (p < 0.001).
The percentage of antibiotic days used for culture-proven
infections (sepsis and/or meningitis) increased from 11.8% and
10.1% in 2015 and 2016 to 23.4% in 2017. The number of culture-
proven infections and concomitant antibiotic days increased
significantly (p < 0.001) due to an increase of community
acquired infections. The number of hospital acquired, culture-
proven infections, and concomitant antibiotic days decreased
significantly (p< 0.001). The annual comparison of correct initial
antibiotic use for culture proven infections and the rate of correct
streamlining remained mainly unchanged. The rate of correct
initial antibiotic use for culture proven infections was between
82 and 90%, streamlining was correct in 80–90% of the cases.
Table 3 gives an overview of all results. Figure 2 depicts the
results as relative annual index to 2015 (base 100%).
DISCUSSION
The annual comparison of overall antibiotic days per 1000 patient
days and antibiotic days for culture-negative situations showed
a significant improvement over the 3 years. Furthermore,
hospital-acquired infections such as VAP and CLABSI
decreased and the use of broad-spectrum antibiotics such
as meropenem and vancomycin was reduced by more than
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FIGURE 1 | Flow chart illustrating selection process of literature review.
50%. Meanwhile, mortality rates and culture-proven, hospital-
acquired infections remained unchanged. These findings indicate
that quality of antibiotic use and infection control improved
significantly. Correct initial antibiotic use was around 80–90%
and streamlining remained unchanged by 70–80% over the study
period.
Antibiotic days per 1000 hospitalization days are difficult
to compare between different units as NICU and PICU’s
often have different infrastructures and diverse patient spectra.
Therefore, it is not possible to assess the absolute number of 400
antibiotic days per 1000 patient days. Similarly, the comparison
of meropenem and vancomycin use within the literature is
difficult to assess. However, there are a few reports in line with
our findings with successful reduction of their use in time series
in NICU/PICUs after introducing an AMS (38–40). Analog,
there are reports regarding a high variation of antibiotic use in
different NICUs with unchanged outcomes indicating potential
overuse (5, 41, 42). Cantey reports a rate of 89% of empirically
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TABLE 1 | Overview of publications used in the review.
Author Year Study design Setting Title Key messages Main outcome
Van Buul
Laura et al.
(33)
2014 Qualitative Study Tertiary care center,
community hospitals,
nursing homes and
residential care facilities
in Netherland
“Participatory action research in
antimicrobial stewardship: a
novel approach to improving
antimicrobial prescribing in
hospitals and long-term care
facilities”
The study indicates, that the
collaborative nature of the
participatory action research
results in greater engagement
compared with top-down
approaches
Improvement in
antimicrobial
prescription
Jeffs et al.
(34)
2015 Qualitative study Intensive care units of 3
teaching hospitals in
Toronto and Ontario
“A qualitative analysis of
implementation of antimicrobial
stewardship at 3 academic
hospitals: Understanding the key
influences on success”
Successful implementation of an
antimicrobial stewardship
program should include the
following key themes: 1.Get the
right people on board; 2.Build
collegial relationships (formally
and informally) with prescribers;
3.Establishing a track record
Successful
implementation of an
antimicrobial
stewardship program
Sinkowitz-
Cochran
(35)
2012 Descriptive survey
based study
Medical, surgical and
intensive care units of
Veterans Affairs
Medical Centres in the
USA
“The associations between
organizational culture and
knowledge, attitudes, and
practices in a multicentre
Veterans Affairs quality
improvement initiative to prevent
methicillin-resistant
Staphylococcus aureus”
Greater engagement of
healthcare personnel is
associated with having a good
leadership structure and the
feeling of being supported by
leadership is positively
associated with better MRSA
prevention practices
Improvement in MRSA
prevention practices
leads to reduced
infection rate
Pronovost
et al. (36)
2016 Quantitative
intervention study
Intensive care units in
Michigan, USA
“Sustaining Reductions in central
line-associated bloodstream
infections in Michigan intensive
care units: a 10-year analysis”
In order to implement and
sustain an improvement in
antimicrobial stewardship the
active involvement of hospital
leaders is important
Reduction of central
line-associated
bloodstream infections
Jain et al.
(37)
2006 Quantitative
intervention study
Single intensive care
unit in Mississippi, USA
“Decline in ICU adverse events,
nosocomial infections and cost
through a quality improvement
initiative focusing on teamwork
and culture change”
Adverse events and nosocomial
infections declined following the
introduction of a changed
system of care in the ICU
Reduction of
nosocomial infections
after intervention
TABLE 2 | Baseline characteristics of study population on admission.
2015 2016 2017
ADMISSIONS AND PATIENTS
Admissions (n) 556 575 571
Patients total (n) 521 518 528
Newborns <44 weeks of gestational
age (n)
Percentage of newborns <44 weeks on
gestational age on patients total (%)
302
58.0
299
57.7
291
55.1
Preterm infants <32 weeks of gestational
age (n)
Percentage of preterm infants <32 weeks
of gestational age on patients total (%)
63
12.1
76
14.7
82
15.5
Preterm infants <28 weeks of gestational
age (n)
Percentage of preterm infants <28 weeks
of gestational age on patients total (%)
22
4.2
23
4.4
26
4.9
ADMISSION SCORES
CRIB II (mean ± SD) 6.5 (±2.8) 6.0 (±2.8) 5.7 (±2.5)
PIMS II (mean ± SD) 3.4 (±9.7) 3.9 (±9.9) 5.4 (±12.3)
prescribed antibiotics for culture-negative situations in their
NICU which is in line with our findings in the years 2015 and
2016 (9). With increasing numbers of multi-resistant bacteria
particularly on ICU’s and the growing body of knowledge on the
negative effects of antibiotics on the individual microbiome with
potential impact on future health, there is a mandatory request
for every unit to assess, evaluate and minimize antibiotic use
(11, 13–19). The structural interventions which were introduced
to our unit had a clearly positive effect on overall antibiotic
use, reducing the overall consumption and increasing the rate of
antibiotics used for culture-proven infections. We do interpret
this as a step in the aimed direction. Furthermore, mortality
rates within the study period showed a decreasing trend, which
was not statistically significant due to the low rate of mortality.
Nevertheless, recent publications underline this result, showing
an association between overuse of antibiotics and increased
short-term morbidity and mortality (13).
With successful implementation of AMS programs it is
possible to reduce hospital-acquired infections as VAP and
CLABSI rates (36, 37, 43). The observed rate of 3.1 VAP episodes
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TABLE 3 | Annual comparison of outcomes.
2015 2016 2017 P values
ANTIBIOTIC USE OVERALL
Patient days (n) 2628 2729 2518 NA
Antibiotic days per 1000 patient days (n) 474.1 398.3 403.9 p < 0.001a
Antibiotic days for culture-negative situations per 1000 patient days (n) 418.2 358.0 309.4 p < 0.001a
Meropenem days per 1000 patient days (n) 53.2 27.4 25.5 p < 0.001a
Vancomycin days per 1000 patient days (n) 86.8 43.1 33.1 p < 0.001a
HOSPITAL ACQUIRED INFECTIONS: VAP
Ventilation days (n)
Percentage of ventilation days on patient days (%)
956
36.4
739
27.1
545
21.6
p < 0.001a
Suspected VAP per 1000 ventilation days (n) 26.2 19.0 9.2 p = 0.027c
Proven VAP per 1000 ventilation days (n) 3.1 0 0 NA
Antibiotic days for suspected VAP per 1000 ventilation days (n) 214.4 150.2 56.9 p < 0.001a
Antibiotic days for proven VAP per 1000 ventilation days (n) 32.4 0 0 p < 0.001a
HOSPITAL ACQUIRED INFECTIONS: CLABSI
Catheter days (n)
Percentage of catheter days on patient days (%)
1687
64.2
1618
59.3
1197
47.5
p < 0.001a
Suspected CLABSI per 1000 catheter days (n) 10.7 8.7 6.7 p = 0.261c
Proven CLABSI per 1000 catheter days (n) 1.8 0.6 0 p = 0.156c
Antibiotic days for suspected CLABSI per 1000 catheter days (n) 70.0 63.7 33.4 p < 0.001a
Antibiotic days for proven CLABSI per 1000 catheter days (n) 17.8 4.3 0 p < 0.001a
CULTURE PROVEN INFECTIONS
Positive blood cultures (n) 10 10 17 p = 0.129d
Positive blood cultures within 48 h of hospitalization (=community acquired infections) 4 2 12
p = 0.034b
Positive blood cultures after 48 h of hospitalization (=hospital acquired infections) 6 8 5
Positive CSF cultures (n) 1 0 0 NA
Antibiotic days for culture proven infections per 1000 patient days (n) 55.9 40.3 94.5 p < 0.001a
Antibiotic days for community acquired, culture proven infections per 1000 patient days (n) 14.8 8.4 71.5 p < 0.001a
Antibiotic days for hospital acquired, culture proven infections per 1000 patient days (n) 41.1 31.9 23.0 p < 0.001a
Percentage of antibiotic days for culture proven infections (%) 11.8 10.1 23.4 NA
Correct initial antibiotic use (n)
Percentage of correct initial antibiotic use (%)
9/10
90.0
9/10
90.0
14/17
82.4
p = 1b
Correct streamlining (n)
Correct streamlining (%)
7/10
70.0
8/10
80.0
12/17
70.6
p = 0.902b
MORTALITY
Mortality all patients (n)
Mortality all patients (%)
11
2.1
8
1.5
8
1.5
p = 0.760b
Mortality newborns <44 weeks of gestational age (n)
Mortality newborns <44 weeks of gestational age (%)
10
3.3
6
2.0
5
1.7
p = 0.467b
aCuzick’s nonparametric test for trend; bFisher’s exact test; cPoisson regression (adjusted for number of ventilation or catheter days); dPoisson regression (adjusted for number of
patient days); NA, not applicable.
per 1000 ventilation days and 1.8 CLABSI episodes per 1000
catheter days in 2015 is within the published range of hospital-
acquired infections (29, 44). Nevertheless, in 2017 we achieved a
blank sheet without any confirmed VAP or CLABSI. Most studies
report only rates of confirmed hospital-acquired infections as
VAP and CLABSI, which has become accepted quality indicators
for intensive care units. Our findings indicate that there is a
high variance between suspected and proven hospital-acquired
infections with concomitant antibiotic use. Fisher et al. reported
that 47% of antibiotic prescriptions in a PICU were due to
suspected VAP (8). Cantey reported that 62% of antibiotic
courses over 5 days for culture-negative situations in their
NICU were for suspected pneumonia (9). Therefore, assessment,
evaluation, and reduction of suspected and confirmed hospital-
acquired infections has to become the standard measure for
quality improvement initiatives.
In this single center study, AMS in regards to antibiotic use
and hospital-acquired infections improved remarkably over the
3 years. The unit’s surveillance program for AMS was introduced
in October 2014 and therefore already in place 2015. The new
head of unit did not just set up an AMS program because
he had the goal to do so. Through multifaceted changes after
Frontiers in Pediatrics | www.frontiersin.org 8 October 2018 | Volume 6 | Article 294
Steinmann et al. Empowering Leadership and AMS
FIGURE 2 | Relative annual index to 2015 (base 100%) of antibiotic days overall, meropenem and vancomycin days, and antibiotic days for hospital acquired,
culture-proven infections, and culture-negative situations per 1000 patient days; not shown are antibiotic days for community acquired, culture-proven infections
because development of infection is independent of the unit; *Culture-negative situations: suspected infections and prophylaxis; aCuzick’s non-parametric test for
trend: p < 0.001.
discussion within the team, i.e., the early extubation policy, team
members were empowered to take over direct responsibility for
their patients. Based on the overarching goal to optimize care,
AMS was just part of it and goals were set through everyone on
the team. This is a keymessage of successful changemanagement:
The statement “successful change leadership involves investing
time in finding common ground across stakeholders and in
building credibility and trust“ (45) accentuates the fact, that in
order to successfully implement a change, stakeholders need to
define their own goals (46, 47). The potential of empowerment
as leadership style lies in the fact that the members of the team
receive a sense of meaning and coherence through their self-
developed goals. This also leads to the phenomenon that the
team members remain committed to the project because they
want to achieve their previously self-defined visions. The leader
does not delegate orders top-down, but builds a team of direct
caregivers and empowers them to take over responsibility and
make their own decisions. The leader is perceived as a coach
(48). Leadership who enables team members to take over direct
responsibility and which emphasize the importance of a positive
team atmosphere is well known in industries outside health care
(49, 50). Literature in health care is relatively scarce and mainly
focused on nursing staff (38). Those articles often focus only on
the qualitative impact of leadership style on the team such as job
satisfaction (51, 52).
The need of a strong leadership in order to implement a
quality improvement program is mentioned in several studies
(46, 53, 54). The CDC guidelines for the implementation of
an AMS program mention leadership commitment as the first
of their 7 core elements (55). The wording “strong leadership”
though bears the potential of different definitions of leadership
styles. Obviously, a rather directive, control-driven leadership
style can be strong and effective: In trauma care the optimal
style and leadership depends on patient characteristics and
team composition. Directive leadership in an emergency trauma
room is most effective when pressure and urgency is high and
teams are inexperienced (45). But individual competence and
autonomy was a corner stone of physician’s education and
development during the last few decades (56–58). Therefore,
physicians often do not like to be told what to do and prescriber
opposition is one of the barriers of successful implementation
of AMS programs (21, 59). This is in contrast to the current
recommendations of AMS programs: The strategy with the best
evidence consists of a multidisciplinary team, which ideally
includes an infectious diseases physician (leading/directing the
program), a clinical pharmacist with infectious diseases training,
a clinical microbiologist, an information system specialist, an
infection control professional and a hospital epidemiologist (2).
The AMS team is like a control system giving directive orders
to the frontline physicians. Empowering leadership for front-line
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physicians regarding AMS is an alternative way andmay improve
implementation of AMS even when the respective staff and
financial resources for a comprehensive AMS program are not
available.
The few articles that we found within the literature review
regarding leadership and AMS agree that an empowering
leadership style leads to a higher engagement of staff and may
have positive impacts on prevention of MRSA infections (35),
reduction of nosocomial infections (37) and CLABSI (36). This
is in line with the results of our study that the significantly
reduced rate of hospital-acquired infections is at least partly
due to the empowering leadership style. As example, the fact
that physicians as direct caregivers were enabled to extubate
earlier leads to shorter duration of ventilation, reduces the risk
of VAP, and may be collaterally responsible for the reduction
of catheter days with a reduced risk of CLABSI. Similar, to
stop antibiotic therapy early in culture negative situations may
be seen as evident, best practice. Nevertheless, frontline staff
needs to be empowered to do so through education and without
being at risk to be blamed. The prerequisite for empowering
team members is education (37): Staff members need to be
educated before and while an intervention or change, in order
to gain the required knowledge and skills to be able to take
over responsibilities. Therefore, an empowering leadership style
requires not only a compliant leader, but also a suitable team.
Jeffs et al. describe it as “getting the right people on board” (34).
Jain et al. mentioned a culture change with better communication
within a multidisciplinary team and a stronger feeling of penalty-
free unity as an important strategy in order to reduce nosocomial
infections and having a better coordinated team (37). On the
other hand, actions like the stewardship rounds held once a
week with the infectious disease specialist in our unit seem
to be insufficient to improve streamlining. Similar, the practice
of correct initial use of antibiotics was high with 90% in the
first 2 years of the study, but showed a decreasing trend.
Whereas streamlining is probably less influenced by empowering
leadership and more a problem of knowledge and education,
reduced correct initial antibiotic therapy may be a side effect of
empowering and individual autonomy of physicians.
Our study has several limitations. Obviously and most
important, the connection between the significantly improved
AMS data and the change of leadership style is only an
association. There were multifaceted changes during the study
period and therefore there is no proof of this relationship.
Through leadership change and multifaceted changes the
awareness and compliance for infection precautions and rational
antibiotic use may increase. On the other hand, many parts of
the implemented changes as for example early extubation or
early stop of antibiotic therapy were dependent on empowered
frontline physicians encouraged to do it. Obviously, it is possible
that similar results could be achieved through daily visits
of an infectious disease specialist and by strengthening the
multidisciplinary approach. However, empowering leadership
may serve as an add on or an option if resources are limited.
Furthermore, the analysis uses the outcome data of 2015 as
baseline and we have no data to show that they are representative
for former years. Third, we did not measure the change
of leadership style objectively. Nevertheless, we observed a
significant improvement over a period of 3 years with a mainly
unchanged physician team and steady baseline characteristics of
admitted patients.
CONCLUSION
Based on our findings with clearly improved antibiotic use
and reduced rate of hospital-acquired infections, we conclude
that an empowering leadership style which focuses on enabling
frontline physicians to take over direct responsibilities for their
patients may be a successful strategy to improve antimicrobial
stewardship.
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